GlassScriptPhysician profile
Belal Said
NPI 1831376961
$2,761.37
in general payments reported to CMS, 2019-2025
12 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $177 · 2021: $28.57 · 2022: $26.32 · 2023: $550 · 2024: $599 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $900.19 | 2019-2024 | |
| Abbvie INC. | $505.52 | 2019-2025 | Rinvoq |
| Amgen INC. | $470.13 | 2019-2024 | Enbrel, Otezla |
| Celgene Corporation | $320.40 | 2019 | |
| Pfizer INC. | $217.86 | 2019-2021 | |
| Ucb, INC. | $166.77 | 2019-2020 | |
| Genentech USA, INC. | $100.00 | 2019 | |
| Recor Medical INC | $23.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Corcept Therapeutics | $18.81 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.97 | 2024 | Strensiq |
| Novo Nordisk INC | $13.58 | 2020 | |
| Medexus Pharma, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belal Said listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.